Stockscreener 앱 받기
1.275
0.01%
-0.005
전일 마감가:
$1.28
열려 있는:
$1.28
하루 거래량:
91,137
Relative Volume:
0.07
시가총액:
$2.88M
수익:
-
순이익/손실:
$-33.44M
주가수익비율:
-1.6901
EPS:
-0.7544
순현금흐름:
$-28.30M
1주 성능:
-17.43%
1개월 성능:
-31.19%
6개월 성능:
-62.90%
1년 성능:
-87.51%
1일 변동 폭
$1.25
$1.29
1주일 범위
$1.25
$1.5894
52주 변동 폭
$1.25
$19.41
Nucana Plc Adr Stock (NCNA) Company Profile
NCNA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| NCNA | 1.27 | 2.88M | 0 | -33.44M | -28.30M | -0.7544 |
| VRTX | 450.09 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 747.09 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.88 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 245.68 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.62 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Nucana Plc Adr Stock (NCNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-03-03 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2020-10-22 | 개시 | Truist | Buy |
| 2020-07-24 | 개시 | Oppenheimer | Outperform |
| 2019-08-19 | 개시 | H.C. Wainwright | Buy |
| 2018-10-19 | 개시 | Piper Jaffray | Overweight |
| 2017-10-23 | 개시 | Citigroup | Buy |
| 2017-10-23 | 개시 | Jefferies | Buy |
| 2017-10-23 | 개시 | William Blair | Outperform |
모두보기
Nucana Plc Adr 주식(NCNA)의 최신 뉴스
Trading Day Triumph: NuCana plc ADR (NCNA) Ends at 2.45, a -10.91 Surge/Plunge - The Dwinnex
Get in on NuCana plc ADR’s (NCNA) buy-in window today! - SETE News
NuCana plc ADR Inc. (NCNA) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
NCNA’s price-to-sales ratio: Is it a good investment opportunity? - US Post News
NuCana secures new US patent for cancer treatment NUC-7738 - Investing.com India
Market Watch: NuCana plc ADR (NCNA)’s Noteworthy Drop, Closing at 3.05 - The Dwinnex
Daily Market Movement: NuCana plc ADR (NCNA) Sees a -7.03 Decrease, Closing at 3.44 - The Dwinnex
William Blair downgrades NuCana plc ADR (NCNA) rating to a Mkt perform - Knox Daily
There is no doubt that NuCana plc ADR (NCNA) ticks all the boxes. - SETE News
Wolfspeed Inc [WOLF] Investment Appeal on the Rise - Knox Daily
Labcorp Holdings Inc. (LH) may enjoy gains as insiders got busy in the recent days - Knox Daily
NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study - Yahoo Finance
NCNA’s Financial Health: Exploring NuCana plc ADR’s Debt-to-Equity Ratio of 1.79 - The InvestChronicle
Analyzing NCNA’s price-to-book ratio for the last quarter - US Post News
Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Increases In September - Benzinga
Endava PLC Sponsored ADR (DAVA) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
Opera Limited Sponsored ADR (OPRA) Crossed Above the 20-Day Moving Average: What That Means for Investors - Yahoo Finance
Did Jim Cramer Say Buy Arm Holdings PLC – ADR (NASDAQ:ARM) Industrial Stock Before Rate Cuts? - Yahoo Finance
NuCana price target lowered to $25 from $150 at Oppenheimer - TipRanks
In the Green: NuCana plc ADR (NCNA) Closes at 3.66, Up/Down -52.65 from Previous Day - The Dwinnex
NuCana stock downgraded by William Blair after halted cancer study - Investing.com India
NuCana halts NuTide:323 study on colorectal cancer - Investing.com
NuCana Ends Phase 2 Cancer Study, Focuses on Promising Treatments - TipRanks
Check out these key findings about NuCana plc ADR (NCNA) - SETE News
NCNA’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle
NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire Inc.
NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update - The Bakersfield Californian
NuCana shares receive $150 stock PT at Oppenheimer on upbeat trial prospects - Investing.com
Sea Limited Sponsored ADR (SE) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
XPeng Inc. Sponsored ADR (XPEV) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
Co-Diagnostics (CODX) to Post Q2 Earnings: What's in Store? - Yahoo Canada Shine On
NuCana's Biliary Tract Cancer Candidate Gets Orphan Drug Tag - Yahoo Singapore News
NuCana Stops Patient Enrollment in Pancreatic Cancer Study - Yahoo Sport Australia
Citi Appointed as Successor Depositary Bank for Iberdrola, S.A.’s ADR Programme - Yahoo Finance
NuCana to Participate in the 2022 Jefferies Healthcare Conference - The Globe and Mail
NuCana to Present at the Jefferies Virtual London Healthcare Conference - The Globe and Mail
Blueprint Medicines Files NDA to FDA for Pralsetinib in MTC - Yahoo Lifestyle UK
Analysts Estimate Endava PLC Sponsored ADR (DAVA) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
NuCana (NCNA) Looks Good: Stock Adds 5.7% in Session - Yahoo New Zealand News
Should You Buy NuCana (NCNA) Ahead of Earnings? - Yahoo News UK
Should You Buy ARM Holdings (ARM) Ahead of Earnings? - Yahoo Finance
NuCana plc Announces Reverse ADS Split - TipRanks
Why Sea Limited Sponsored ADR (SE) Might be Well Poised for a Surge - Yahoo Finance
Why Opera Limited Sponsored ADR (OPRA) Outpaced the Stock Market Today - Yahoo Finance
NuCana: Potential Turnaround In 2024 But Risky - Seeking Alpha
Davion Enters into Agreement with The Bank of New York Mellon for ADR Programme and $30 Million IPO Fundraise - Yahoo Finance
Bears are Losing Control Over NuCana PLC Sponsored ADR (NCNA), Here's Why It's a 'Buy' Now - Yahoo Finance
MARKET DATA - The Wall Street Journal
Down 34.6% in 4 Weeks, Here's Why You Should You Buy the Dip in NuCana PLC Sponsored ADR (NCNA) - Yahoo Finance
The Daily Biotech Pulse: Pfizer, BioNTech File Marketing Application In Europe, NuCana Jumps On Data, Amarin Takes On Hikma In Patent Lawsuit - Yahoo Finance
NuCana Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters ... - The Globe and Mail
Nucana Plc Adr (NCNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.80%
0.42%
자본화:
|
볼륨(24시간):